Published in AIDS Weekly, February 19th, 2001
The drug, known as BMS-232632, differs from previous protease inhibitors in part because those drugs have required patients to adhere to complex dosing schedules. Doctors commonly prescribe one of a variety of protease inhibitors, in partnership with drugs called nucleoside analogs, in a pharmaceutical battle plan to combat HIV.
The data were presented by a University of Southern California (USC) researcher at the Eighth Conference on Retroviruses and Opportunistic Infections, held in Chicago, Illinois, during February...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.